Chargement en cours...
An emerging treatment option for glaucoma: Rho kinase inhibitors
Rho kinase (ROCK) inhibitors are a novel potential class of glaucoma therapeutics with multiple compounds currently in Phase II and III US Food and Drug Administration trials in the United States. These selective agents work by relaxing the trabecular meshwork through inhibition of the actin cytoske...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2014
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4025933/ https://ncbi.nlm.nih.gov/pubmed/24872673 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S41000 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|